Treatment outcomes among human epidermal growth factor receptor 2 positive breast cancer patients: A systematic review.

Generally, the overall survival outcome was relatively higher after treatment among HER2 positive breast cancer patients. The addition of trastuzumab in most of the studies has shown improvement in the overall survival and the disease-free survival rate of the study patients.